| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/AJH.23384 |
| P698 | PubMed publication ID | 23349007 |
| P50 | author | Ayalew Tefferi | Q66370740 |
| P2860 | cites work | Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1 | Q27687464 |
| A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia | Q33345998 | ||
| Lenalidomide therapy in myelofibrosis with myeloid metaplasia | Q33370821 | ||
| Palliative goals, patient selection, and perioperative platelet management: outcomes and lessons from 3 decades of splenectomy for myelofibrosis with myeloid metaplasia at the Mayo Clinic | Q33371553 | ||
| New and old treatment modalities in primary myelofibrosis | Q33377528 | ||
| Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele | Q33385124 | ||
| Pomalidomide is active in the treatment of anemia associated with myelofibrosis | Q33385644 | ||
| Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis | Q33386057 | ||
| Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis | Q33391880 | ||
| Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients | Q33392291 | ||
| DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status | Q33393245 | ||
| Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study | Q33394025 | ||
| JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis | Q33399977 | ||
| A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis | Q33399980 | ||
| Outcome of transplantation for myelofibrosis | Q34015474 | ||
| Myelodysplasia with fibrosis: a distinct entity? | Q34353334 | ||
| Acute panmyelosis with myelofibrosis: an entity distinct from acute megakaryoblastic leukemia | Q34373252 | ||
| IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis. | Q34562170 | ||
| Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel | Q34626628 | ||
| Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms | Q36270713 | ||
| TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis | Q36303447 | ||
| Pathogenesis of myelofibrosis with myeloid metaplasia | Q36315447 | ||
| Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms | Q36946576 | ||
| JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials | Q36946580 | ||
| Dynamic model for predicting death within 12 months in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis | Q37163487 | ||
| Conventional cytogenetics in myelofibrosis: literature review and discussion | Q37367516 | ||
| Anti-platelet therapy and aspirin resistance - clinically and chemically relevant? | Q37808243 | ||
| Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. | Q37900078 | ||
| Evidence for the Platelet Specificity of β-Thromboglobulin and Studies on its Plasma Concentration in Healthy Individuals | Q39537002 | ||
| Modified kinetics of platelet-derived growth factor-induced Ca2+ increases in NIH-3T3 cells overexpressing phospholipase C gamma 1. | Q41641749 | ||
| Human factor IX in animals: kinetics from isolated, radiolabelled protein and platelet destruction following crude concentrate infusions | Q42671817 | ||
| Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation | Q43265365 | ||
| Thalidomide treatment in myelofibrosis with myeloid metaplasia | Q43969504 | ||
| Risk factors for leukemic transformation in patients with primary myelofibrosis | Q46650489 | ||
| A patient with myelofibrosis complicated by refractory ascites and portal hypertension: to tips or not to tips? A case report with discussion of the mechanism of ascites formation | Q47654692 | ||
| Erythropoiesis stimulating agents have limited therapeutic activity in transfusion-dependent patients with primary myelofibrosis regardless of serum erythropoietin level | Q48009616 | ||
| Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis. | Q53166045 | ||
| International Prognostic Scoring System-independent cytogenetic risk categorization in primary myelofibrosis. | Q53184187 | ||
| JAK2 germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: nullizygosity for the JAK2 46/1 haplotype is associated with inferior survival. | Q53185401 | ||
| Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera. | Q53544139 | ||
| Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12, and TET2 in myeloproliferative neoplasms. | Q54518446 | ||
| LNK mutations in JAK2 mutation-negative erythrocytosis. | Q54649906 | ||
| Transjugular intrahepatic portosystemic shunt for treatment of portal hypertension due to extramedullary hematopoiesis in idiopathic myelofibrosis | Q57168253 | ||
| P433 | issue | 2 | |
| P921 | main subject | myelofibrosis | Q1752571 |
| chronic idiopathic myelofibrosis | Q3857106 | ||
| P304 | page(s) | 141-150 | |
| P577 | publication date | 2013-02-01 | |
| P1433 | published in | American Journal of Hematology | Q4744246 |
| P1476 | title | Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management | |
| P478 | volume | 88 |
| Q38586421 | A comprehensive review of pacritinib in myelofibrosis |
| Q33420095 | A multinational, open-label, phase 2 study of ruxolitinib in Asian patients with myelofibrosis: Japanese subset analysis |
| Q37740928 | A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence |
| Q38437236 | Acute duodenal ischemia and periampullary intramural hematoma after an uneventful endoscopic retrograde cholangiopancreatography in a patient with primary myelofibrosis |
| Q33556843 | Allogeneic transplantation for primary myelofibrosis with BM, peripheral blood or umbilical cord blood: an analysis of the JSHCT |
| Q33436416 | Alternative agents to prophylactic platelet transfusion for preventing bleeding in people with thrombocytopenia due to chronic bone marrow failure: a meta-analysis and systematic review |
| Q24186703 | Alternative agents versus prophylactic platelet transfusion for preventing bleeding in patients with thrombocytopenia due to chronic bone marrow failure: a network meta-analysis and systematic review |
| Q38236642 | An update on allogeneic hematopoietic progenitor cell transplantation for myeloproliferative neoplasms in the era of tyrosine kinase inhibitors |
| Q33436685 | Assessing the safety and efficacy of ruxolitinib in a multicenter, open-label study in Japanese patients with myelofibrosis |
| Q52813540 | Austrian recommendations for the management of primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis: an expert statement. |
| Q38715095 | Cell autonomous expression of CXCL-10 in JAK2V617F-mutated MPN. |
| Q38242725 | Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) |
| Q36817560 | Comorbidities predict worse prognosis in patients with primary myelofibrosis |
| Q38187675 | Cooperation between pathologists and clinicians allows a better diagnosis of Philadelphia chromosome-negative myeloproliferative neoplasms. |
| Q45979316 | Cytogenetic studies and their prognostic contribution in 565 Chinese patients with primary myelofibrosis. |
| Q35525312 | Discrepancy in diagnosis of primary myelofibrosis between referral and tertiary care centers |
| Q42723157 | Does angiogenesis matter in primary myelofibrosis? |
| Q37035925 | Efficacy and safety of ruxolitinib in the treatment of patients with myelofibrosis. |
| Q50857194 | Elevated C-reactive protein is associated with shortened leukemia-free survival in patients with myelofibrosis. |
| Q53646641 | Flow cytometry immunophenotypic analysis of Philadelphia-negative myeloproliferative neoplasms: Correlation with histopathologic features. |
| Q59135610 | Genetic predictors of response to specific drugs in primary myelofibrosis |
| Q26778326 | Guidelines for the management of myeloproliferative neoplasms |
| Q37401358 | Impact of JAK2V617F Mutational Status on Phenotypic Features in Essential Thrombocythemia and Primary Myelofibrosis. |
| Q92027170 | Indications for Surgery in Non-Traumatic Spleen Disease |
| Q26774212 | Inflammation as a Keystone of Bone Marrow Stroma Alterations in Primary Myelofibrosis |
| Q34137469 | Intestinal obstruction caused by extramedullary hematopoiesis and ascites in primary myelofibrosis |
| Q40892218 | Iron chelation therapy with deferasirox in the management of iron overload in primary myelofibrosis |
| Q39232415 | Management of myelofibrosis: JAK inhibition and beyond |
| Q41980585 | Mayor erythropoietic response after deferasirox treatment in a transfusion-dependent anemic patient with primary myelofibrosis |
| Q38805429 | Molecular biomarkers of thrombosis in myeloproliferative neoplasms |
| Q38481945 | Molecular genetic evaluation of myeloproliferative neoplasms |
| Q44429606 | Mutations and prognosis in primary myelofibrosis |
| Q45090920 | Myelofibrosis, diffuse alveolar hemorrhage and radiation treatment |
| Q47168907 | Peritoneal carcinomatosis-like implants of extramedullary hematopoiesis. An insolite occurrence during splenectomy for myelofibrosis |
| Q38931426 | Primary myelofibrosis and its targeted therapy. |
| Q52862082 | Problems and pitfalls in grading of bone marrow fibrosis, collagen deposition and osteosclerosis - a consensus-based study. |
| Q42051491 | Prognostic significance of ASXL1, JAK2V617F mutations and JAK2V617F allele burden in Philadelphia-negative myeloproliferative neoplasms |
| Q38815464 | Pruritus in primary myelofibrosis: management options in the era of JAK inhibitors |
| Q42111169 | Resolution of myelofibrosis-associated pulmonary arterial hypertension following allogeneic hematopoietic stem cell transplantation |
| Q33421596 | Response to ruxolitinib in patients with intermediate-1-, intermediate-2-, and high-risk myelofibrosis: results of the UK ROBUST Trial |
| Q40045490 | Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report |
| Q41519422 | Ruxolitinib Treatment in a Patient with Primary Myelofibrosis Resistant to Conventional Therapies and Splenectomy: A Case Report |
| Q47097176 | Ruxolitinib in Myelofibrosis and Polycythemia Vera |
| Q33432637 | Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial |
| Q38567540 | Setting Appropriate Goals for the Next Generation of Clinical Trials in Myelofibrosis |
| Q38193610 | Targeting hedgehog signaling in myelofibrosis and other hematologic malignancies |
| Q34840082 | The Burden of JAK2V617F Mutated Allele in Turkish Patients With Myeloproliferative Neoplasms |
| Q36364763 | The Clinical Significance of IDH Mutations in Essential Thrombocythemia and Primary Myelofibrosis |
| Q34861658 | The methyltransferase EZH2 is not required for mammary cancer development, although high EZH2 and low H3K27me3 correlate with poor prognosis of ER-positive breast cancers |
| Q38403573 | The use of erythropoiesis-stimulating agents with ruxolitinib in patients with myelofibrosis in COMFORT-II: an open-label, phase 3 study assessing efficacy and safety of ruxolitinib versus best available therapy in the treatment of myelofibrosis |
| Q35988523 | Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase |
| Q51737052 | Understanding Splenomegaly in Myelofibrosis: Association with Molecular Pathogenesis. |
Search more.